Roxee Medication Guide

Cefovecin

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Powder Multiple FDA sponsors Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Aug 6, 2026, 7:46 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Aug 6, 2026, 7:46 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:46 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Illustration placeholder

Cefovecin

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Powder Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Cefovecin

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). Species commonly shown: Both, Dog, Cat.

Generic name

Cefovecin

Brand names

Convenia®, Cefovecin Sodium for Injection

Manufacturer

Multiple FDA sponsors

Species

Both, Dog, Cat

Dosage forms

Powder, Lyophilized powder for injection

Prescription

Prescription required

Completeness

100%

Validation

Needs review

Brand names

Convenia® Cefovecin Sodium for Injection

Dosage forms

Powder Lyophilized powder for injection

Indications / Uses

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Anorexia, Diarrhoea, Not eating.

FAQ

Both, Dog, Cat

Yes. Roxee shows this as prescription-only.

Powder, Lyophilized powder for injection

Related Medications

Related Conditions

Abscesses (cat bite abscess) Pyoderma (superficial/deep)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/849
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17145
Last refreshed: Aug 6, 2026, 7:46 p.m.
Last verified: Apr 15, 2026, 10:04 a.m.
Validation status: Needs review

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

For subcutaneous use in dogs and cats only
Maximum treatment should not exceed 2 injections
wobbly/unsteady walking (1 reports)
Loss of appetite (1 reports)
Bilirubinuria (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Cefovecin; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-014449

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 26 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-014449

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-014449

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Bilirubinuria (1 reports), Behavioral disorder (unspecified) (1 reports), Basophilia (1 reports)

Body systems represented Signal grouping

Digestive (1), Skin & allergy (4), Neurologic (1), Behavior (2)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (26 reports), Dog (6 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (3), Schnauzer - Miniature (1), Domestic Longhair (1), Ragdoll (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Cefovecin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

For subcutaneous use in dogs and cats only, Maximum treatment should not exceed 2 injections, wobbly/unsteady walking, Loss of appetite, Bilirubinuria

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Cefovecin brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2026-US-014449 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
SPL · document · documents
FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 15, 2026, 10:04 AM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
openFDA case USA-USFDACVM-2026-US-014449 · adverse_reaction
FOI · document

Safety & side effects

Side effects to monitor:

For subcutaneous use in dogs and cats only
Maximum treatment should not exceed 2 injections
wobbly/unsteady walking
Loss of appetite
Bilirubinuria

Most reported reactions:

Unsteady walking (ataxia) (1 reports)
Loss of appetite (1 reports)
Bilirubinuria (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Cat, Dog

Indication / use

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus …

Form / route / dose

Form: Lyophilized powder for injection, Powder
Route: Subcutaneous
Confirm product label and patient-specific plan.

Warnings

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and …

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

Cefovecin Sodium for Injection SPL
Convenia® SPL
FOI Summary oA 200-812 Approved June 24, 2025.pdf FOI

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA sponsors

Form: Lyophilized powder for injection, Powder

Identifiers:

ANADA: 200812 NADA: 141285 NDC Package: 17033-002-01 NDC Package: 54771-1520-1 NDC Product: 17033 NDC Product: 54771

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200812 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141285 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Selected filters

Body system: Other Clear

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Lethargy (see also Central nervous system depression in Neurological) (16) Intentional misuse (12) Not eating (12) Behavioural disorder NOS (10) Other (62) Neurologic (27) Digestive (26) Effectiveness (12)

Showing up to 50 matching reports. Narrow filters to inspect the remaining reports.

USA-USFDACVM-2026-US-014449

Received 2026-03-25 · MSK · MSK

Serious

Species: Dog
Breed: Schnauzer - Miniature
Size / weight: 10-24 lb (10.16 Kilogram)
Age: 4-7 years (5 Year)
Sex: Male Neutered
Region: USA
Reactions: LamenessWobblinessLethargy (see also Central nervous system depression in Neurological)Unable to walkWeaknessFeverImmune-mediated polyarthritisGastritisAbdominal cavity disorder NOSAbnormal ultrasound findingHyperproteinaemiaLymphopeniaEosinopeniaMedication error NOS
Body systems: OtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-014426

Received 2026-03-25 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (3.27 Kilogram)
Age: 8+ years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: AnorexiaIntentional misuseAdipsiaConstipationLethargy (see also Central nervous system depression in Neurological)AtaxiaHiding
Body systems: DigestiveOtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-014378

Received 2026-03-25 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Longhair
Size / weight: Under 10 lb (2.88 Kilogram)
Age: 8+ years (18 Year)
Sex: Female Unknown
Region: USA
Reactions: Intentional misuseAtaxiaLumbar pain
Body systems: OtherNeurologic
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-014167

Received 2026-03-19 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (1.4 Kilogram)
Age: Under 1 year (11 Week)
Sex: Male Intact
Region: USA
Reactions: Soft stoolBloatedDisorder of gastrointestinal floraEmesis (multiple)DepressionIncreased heart rateBloody stoolBloody diarrhoea
Body systems: OtherDigestiveNeurologic
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-013786

Received 2026-03-19 · MSK · MSK

Non-serious

Species: Cat
Breed: Cat (other)
Sex: Unknown
Region: USA
Reactions: Lack of efficacy - NOSMedication error NOS
Body systems: EffectivenessOther
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-012908

Received 2026-03-19 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.9 Kilogram)
Age: 8+ years (11 Year)
Sex: Female Neutered
Region: USA
Reactions: Thrombocytopenia
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2026-US-013736

Received 2026-03-17 · MSK · MSK

Serious

Species: Dog
Breed: Shepherd Dog - Australian
Size / weight: Under 10 lb (3.45 Kilogram)
Age: Under 1 year (2 Month)
Sex: Female Intact
Region: USA
Reactions: Lethargy (see also Central nervous system depression in Neurological)VomitingAnorexiaTachycardiaFeverIncreased salivationAbnormal radiograph findingNeurological signs NOSIntentional misuseAgitation
Body systems: NeurologicDigestiveOther
Outcomes: Ongoing